Here in the US, there are newer options for HIV prevention but these tools will have limited impact on helping to end the epidemic without active community engagement and uptake. PrEP, one of these newer options, for those at highest risk – gay/MSM and women of color and transgender people – has the potential to reduce incidence and save funds over the long term as one component of high impact prevention. Although the FDA approved daily Truvada as PrEP in 2012, the CDC estimates that approximately 500,000 people in the United States may benefit from PrEP but only a fraction are currently using it. This Workshop aims to build community understanding for existing and upcoming PrEP regimens so that these strategies do not go underutilized. By understanding the research data participants will be able to cite the evidence and engage in cogent dialogue in support of uptake in their respective communities, nationwide.